(h) Neither Takeda nor its related companies have been excluded from the FDA or are subject to a similar sanction from other regulatory authorities in the territory, and neither Takeda nor any of its related companies has used any person who has been excluded by such a regulatory authority in connection with this agreement or any other ancillary clause (if any) , or undertakes in any capacity under this agreement or any ancillary agreement (if it exists). , or is the subject of a conviction described in Section 306 of the FFDCA. Takeda will promptly notify the licensee in writing whether he or any person mandated by Takeda or any of its related companies that operates under this agreement or any other ancillary clause (if any), or who is the subject of a conviction as described in Section 306 ffDCA, or if an action, action , an action, investigation or judicial or administrative proceeding is pending, or to find out Takeda`s knowledge, takeda is threatened with regard to the prohibition or conviction of Takeda, one of its affiliates or such a person who conducts activities. (e) be discovered or developed independently or on behalf of the receiving party or one of its related companies, without the confidential information provided by the party dividing it being used or accessible; or (a) exports. The licenseee shall not induce its related or under-licensed companies to sell or promote, directly or indirectly, through a third party (i) a product outside (g) where confidential information is disclosed in accordance with this section 11.3, such disclosure should not lead to such information being no longer confidential. , unless such disclosure results in a public disclosure of this information (except in the event of a violation of this agreement). Notwithstanding the foregoing, where it is not possible to do so, it must provide the other party with appropriate notice of such disclosure and the use of such information in accordance with the provisions of item (a) (d) of this section 11.3 and, if this is not possible, it must inform the other party appropriately and makes no less than the same efforts to ensure the confidential processing of that information. , that it would have to protect its own confidential information from disclosure, and is collectively and repeatedly responsible for the violation of this Article 11. 1.62 “The Taker`s Know-how” refers to all information and inventions controlled by the taker (with L`Abl-tohne, from the date of entry into force or for the duration necessary to exploit compounds or products in the field, including all information disclosed by the taker to Takeda in accordance with Section 12.2. The licensee`s know-how excludes any information or invention contained in a licensee`s patent. (b) To the extent that existing legislation permits, all staff members of the licensee or his related companies operating under this agreement are required to transfer all rights, titles and interests on and over their inventions and other know-how, whether patentable or not, and to transfer intellectual property rights to the licensee or related companies as exclusive owners. Takeda is not required to participate in the remuneration of an inventor employed by the licensee or by any of its related companies with respect to inventions, information and discoveries as well as intellectual property rights attributed to the licensee or his related companies. The licensee pays, if necessary, all remunerations that are due to these inventors with respect to these inventions and other intellectual property know-how and rights containing them.
8.12 Review. The underwriter maintains complete and accurate records in sufficient detail to enable Takeda to confirm the accuracy of the calculation of royalties and other payments made under this agreement.